Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib monotherapy or chemotherapy combination after first-line failure in advanced non-squamous non-small cell lung cancer
ChiCTR1900022088Phase 4Not yet recruiting
- Sponsor
- Central Hospital Affiliated to Shandong First Medical University
- Start
- Apr 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Central Hospital Affiliated to Shandong First Medical University. Primary endpoints: progression-free survival and objective response rate. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900022088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022088.